These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 23203082)
1. Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? Jalilian B; Einarsson HB; Vorup-Jensen T Int J Mol Sci; 2012 Nov; 13(11):14579-605. PubMed ID: 23203082 [TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Weber MS; Hohlfeld R; Zamvil SS Neurotherapeutics; 2007 Oct; 4(4):647-53. PubMed ID: 17920545 [TBL] [Abstract][Full Text] [Related]
4. The Evolving Mechanisms of Action of Glatiramer Acetate. Prod'homme T; Zamvil SS Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29440323 [TBL] [Abstract][Full Text] [Related]
5. The use of glatiramer acetate in the treatment of multiple sclerosis. Wolinsky JS Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839 [TBL] [Abstract][Full Text] [Related]
6. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Sormani MP; Bruzzi P; Comi G; Filippi M Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228 [TBL] [Abstract][Full Text] [Related]
7. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study). Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086 [TBL] [Abstract][Full Text] [Related]
8. Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis. Peterka M; Valis M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Klimova B; Stourac P; Pavelek Z; Novotny M Eur Neurol; 2023; 86(5):334-340. PubMed ID: 37473734 [TBL] [Abstract][Full Text] [Related]
9. Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice. Mitsikostas D; Bakirtzis C; Nikolaidis I; Tsimourtou V; Kountra P; Matsi S; Papadimitriou A Neurodegener Dis Manag; 2022 Dec; 12(6):311-322. PubMed ID: 36178000 [TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Johnson KP Expert Opin Drug Metab Toxicol; 2010 May; 6(5):643-60. PubMed ID: 20397968 [TBL] [Abstract][Full Text] [Related]
11. Recent insights into the mechanism of action of glatiramer acetate. Kala M; Miravalle A; Vollmer T J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. Arnon R; Aharoni R J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693 [TBL] [Abstract][Full Text] [Related]
13. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Weinstein A; Schwid SR; Schiffer RB; McDermott MP; Giang DW; Goodman AD Arch Neurol; 1999 Mar; 56(3):319-24. PubMed ID: 10190822 [TBL] [Abstract][Full Text] [Related]